Celularity Receives Fast Track Designation from US FDA for Its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/Neu Positive Gastric and Gastroesophageal Junction Cancers

Celularity Inc. announced the US FDA has granted Fast Track Designation for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-101, which is being developed in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.